111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
On September 24, 2020, 111, Inc. (NASDAQ: YI) hosted its 3rd annual China Online Healthcare Summit in Shanghai, focusing on healthcare digitalization. The event gathered around 600 industry leaders and executives, discussing challenges posed by new Chinese regulations and innovations like 111's omni-channel platform. The company announced strategic partnerships with notable firms including Novartis and Bayer. Dr. Gang YU predicts that digital healthcare will surpass real estate and automotive industries in China over the next decade, highlighting 111's role in enhancing healthcare access through technology.
On August 25, 111, Inc. (Nasdaq: YI) and Guangzhou Baiyunshan Pharmaceutical Sales Co., Ltd. signed a strategic cooperation agreement in Shanghai. This partnership aims to innovate digital medicine and enhance the distribution of Baiyunshan's medical products in both online and offline markets. The collaboration will also leverage big data, digital marketing, and patient services to create an effective value chain. This initiative reflects the increasing importance of digital healthcare, especially amid the ongoing COVID-19 pandemic, and aims to improve patient access to medical services in China.
111, Inc. (NASDAQ: YI) reported second quarter 2020 net revenues of RMB1.62 billion (US$229.6 million), marking a 93.5% increase year-over-year. Operating expenses rose to RMB177.5 million (US$25.1 million), but represented a smaller proportion of revenues at 10.9% versus 17.0% last year. The company’s non-GAAP net loss narrowed to 4.9% of revenue, down from 10.1% year-over-year. Notable growth was seen in the B2B segment, with 113.7% revenue growth. The upcoming third quarter outlook projects revenues between RMB2 billion and RMB2.17 billion, indicating continued expansion.
111, Inc. (NASDAQ: YI) announced the completion of a RMB419.82 million (approx. US$60.49 million) capital injection into its principal subsidiary, Yao Fang Shanghai, at a pre-money valuation of US$1.2 billion. The funding aims to enhance the company’s financial flexibility and support plans to list Yao Fang Shanghai on the STAR Market within three years. This strategic move is designed to provide access to new capital and strengthen its position in China's digital healthcare market. The investors have the option to redeem their equity if the listing does not proceed within the specified timeframe.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for the second quarter ending June 30, 2020, before the U.S. market opens on August 20, 2020. An earnings conference call is scheduled for 7:30 AM ET on the same day. The company connects patients with drugs and healthcare services across China through its online platforms and offline network. Interested participants must register online to join the call, and a replay will be available until August 28, 2020. More information can be found on the company’s investor relations website.